These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 35173015)

  • 1. Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.
    Mattsson-Carlgren N; Grinberg LT; Boxer A; Ossenkoppele R; Jonsson M; Seeley W; Ehrenberg A; Spina S; Janelidze S; Rojas-Martinex J; Rosen H; La Joie R; Lesman-Segev O; Iaccarino L; Kollmorgen G; Ljubenkov P; Eichenlaub U; Gorno-Tempini ML; Miller B; Hansson O; Rabinovici GD
    Neurology; 2022 Mar; 98(11):e1137-e1150. PubMed ID: 35173015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration.
    Ortner M; Goldhardt O; Diehl-Schmid J; Yakushev I; Lanz K; Hedderich DM; Manuilova E; Simon M; Weinberger JP; Grimmer T
    J Prev Alzheimers Dis; 2022; 9(3):491-498. PubMed ID: 35841250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid Aβ40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease.
    Baldeiras I; Santana I; Leitão MJ; Ribeiro MH; Pascoal R; Duro D; Lemos R; Santiago B; Almeida MR; Oliveira CR
    J Neurol Sci; 2015 Nov; 358(1-2):308-16. PubMed ID: 26388316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes.
    Lleó A; Irwin DJ; Illán-Gala I; McMillan CT; Wolk DA; Lee EB; Van Deerlin VM; Shaw LM; Trojanowski JQ; Grossman M
    JAMA Neurol; 2018 Jun; 75(6):738-745. PubMed ID: 29554190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropathological changes associated with aberrant cerebrospinal fluid p-tau181 and Aβ42 in Alzheimer's disease and other neurodegenerative diseases.
    Kurihara M; Matsubara T; Morimoto S; Arakawa A; Ohse K; Kanemaru K; Iwata A; Murayama S; Saito Y
    Acta Neuropathol Commun; 2024 Mar; 12(1):48. PubMed ID: 38539238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration.
    Alcolea D; Vilaplana E; Suárez-Calvet M; Illán-Gala I; Blesa R; Clarimón J; Lladó A; Sánchez-Valle R; Molinuevo JL; García-Ribas G; Compta Y; Martí MJ; Piñol-Ripoll G; Amer-Ferrer G; Noguera A; García-Martín A; Fortea J; Lleó A
    Neurology; 2017 Jul; 89(2):178-188. PubMed ID: 28592456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
    Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
    J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
    Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P
    Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures.
    Falgàs N; Ruiz-Peris M; Pérez-Millan A; Sala-Llonch R; Antonell A; Balasa M; Borrego-Écija S; Ramos-Campoy O; Augé JM; Castellví M; Tort-Merino A; Olives J; Fernández-Villullas G; Blennow K; Zetterberg H; Bargalló N; Lladó A; Sánchez-Valle R
    Hum Brain Mapp; 2020 Jun; 41(8):2004-2013. PubMed ID: 31944489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort.
    Schoonenboom NS; Reesink FE; Verwey NA; Kester MI; Teunissen CE; van de Ven PM; Pijnenburg YA; Blankenstein MA; Rozemuller AJ; Scheltens P; van der Flier WM
    Neurology; 2012 Jan; 78(1):47-54. PubMed ID: 22170879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
    Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
    J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers.
    Orduña Dolado A; Stomrud E; Ashton NJ; Nilsson J; Quijano-Rubio C; Jethwa A; Brum WS; Brinkmalm Westman A; Zetterberg H; Blennow K; Janelidze S; Hansson O
    Alzheimers Res Ther; 2024 Jun; 16(1):132. PubMed ID: 38909218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms.
    Irwin DJ; McMillan CT; Toledo JB; Arnold SE; Shaw LM; Wang LS; Van Deerlin V; Lee VM; Trojanowski JQ; Grossman M
    Arch Neurol; 2012 Aug; 69(8):1018-25. PubMed ID: 22490326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics.
    Jeppsson A; Wikkelsö C; Blennow K; Zetterberg H; Constantinescu R; Remes AM; Herukka SK; Rauramaa T; Nagga K; Leinonen V; Tullberg M
    J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1117-1123. PubMed ID: 31167811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects.
    Verwey NA; Kester MI; van der Flier WM; Veerhuis R; Berkhof H; Twaalfhoven H; Blankenstein MA; Scheltens And P; Pijnenburg YA
    J Alzheimers Dis; 2010; 20(2):445-52. PubMed ID: 20164558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy.
    Grothe MJ; Moscoso A; Ashton NJ; Karikari TK; Lantero-Rodriguez J; Snellman A; Zetterberg H; Blennow K; Schöll M;
    Neurology; 2021 Sep; 97(12):e1229-e1242. PubMed ID: 34266917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease.
    Illán-Gala I; Lleo A; Karydas A; Staffaroni AM; Zetterberg H; Sivasankaran R; Grinberg LT; Spina S; Kramer JH; Ramos EM; Coppola G; La Joie R; Rabinovici GD; Perry DC; Gorno-Tempini ML; Seeley WW; Miller BL; Rosen HJ; Blennow K; Boxer AL; Rojas JC
    Neurology; 2021 Feb; 96(5):e671-e683. PubMed ID: 33199433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors.
    Rivero-Santana A; Ferreira D; Perestelo-Pérez L; Westman E; Wahlund LO; Sarría A; Serrano-Aguilar P
    J Alzheimers Dis; 2017; 55(2):625-644. PubMed ID: 27716663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.